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Abstract
Background: Data on combination antiretroviral therapy (cART) in remote rural African regions is increasing.
Methods: We assessed prospectively initial cART in HIV-infected adults treated from 2005 to 2008 at St. Francis
Designated District Hospital, Ifakara, Tanzania. Adherence was assisted by personal adherence supporters. We
estimated risk factors of death or loss to follow-up by Cox regression during the first 12 months of cART.
Results: Overall, 1,463 individuals initiated cART, which was nevirapine-based in 84.6%. The median age was
40 years (IQR 34-47), 35.4% were males, 7.6% had proven tuberculosis. Median CD4 cell count was 131 cells/μl and
24.8% had WHO stage 4. Median CD4 cell count increased by 61 and 130 cells/μl after 6 and 12 months,
respectively. 215 (14.7%) patients modified their treatment, mostly due to toxicity (56%), in particular
polyneuropathy and anemia. Overall, 129 patients died (8.8%) and 189 (12.9%) were lost to follow-up. In a
multivariate analysis, low CD4 cells at starting cART were associated with poorer survival and loss to follow-up (HR
1.77, 95% CI 1.15-2.75, p = 0.009; for CD4 <50 compared to >100 cells/μl). Higher weight was strongly associated
with better survival (HR 0.63, 95% CI 0.51-0.76, p < 0.001 per 10 kg increase).
Conclusions: cART initiation at higher CD4 cell counts and better general health condition reduces HIV related
mortality in a rural African setting. Efforts must be made to promote earlier HIV diagnosis to start cART timely.
More research is needed to evaluate effective strategies to follow cART at a peripheral level with limited technical
possibilities.
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Background
WHO launched the ambitious “3b y5 ” strategy in 2003
following the dramatically improved prognosis of HIV-
infected patients receiving combination antiretroviral
therapies (cART) in industrialized countries [1,2]. This
public health approach aimed to introduce cART at large
scale for resource-constrained countries [3] carrying
most of the HIV attributable disease burden [4]. WHO’s
policy of “universal access” followed in 2007 [5] based on
publications reflecting comparable clinical and immuno-
logical outcomes under cART from different resource-
limited countries [6-17]. The number of people receiving
cART in low- and middle-income countries has increased
13-fold since 2004 and by the end of 2009, an estimated
5.2 million people were receiving cART, which represent
36% of those who need treatment [4].
In 2007, the HIV-prevalence in Tanzania was estimated
to be 5.7% with about 1,867,918 HIV infected Tanzanian
children and adults [18,19]. The HIV incidence slowed to
about 3.4/1000 person-years between 2004 and 2008 [4].
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Tanzania launched the “National HIV/AIDS Care and
Treatment Plan 2003 - 2008” - an initiative to prevent
HIV/AIDS and to provide treatment and care for patients
living with HIV/AIDS [20]. By the end of 2007, 127,895
HIV infected persons received cART with an increase to
154,468 only one year later [4,19]. As in other countries,
the Tanzanian treatment plan was initiated first in large
cities at university and/or referral hospitals. However, a
significant part of HIV-infected Tanzanians live in rural
regions [21,22] and cART evaluations from rural care
and treatment centres in sub-Saharan Africa, and in
particular Tanzania, are still scarce [13,23-27].
We aimed to assess the clinical and immunological
response to cART in a rural treatment centre in Tanzania
emphasizing immunological recovery and risk factors
of death or loss to follow-up during the first year after
starting cART.
Methods
Study design and setting
We analyzed data of a local prospective cohort study of
HIV-infected individuals at the Care and Treatment
Centre of St. Francis Designated District Hospital
(SFDDH) in Ifakara, Tanzania. All HIV-infected adults
initiating cART between 1
st January 2005 and 20
th
December 2008 at the SFDDH were included in this
study.
The SFDDH is the most important health care facility
in the rural Kilombero and Ulanga District of the Moro-
goro Region in Southern Tanzania, providing treatment
and care for a population of about 600,000 inhabitants
and an estimated 30,000 patients living with HIV/AIDS
[5]. Established in 2004, the Chronic Disease Clinic at
St. Francis Designated District Hospital was the first
rural clinic accredited to be a Care and Treatment Cen-
tre of the National AIDS Control Programme (NACP)
in the whole of Tanzania [28]. By December 2008, the
Care and Treatment Centre at SFDDH had enrolled
3,440 patients living with HIV/AIDS. Of these, 2,445
were followed-up on a permanent basis, and 1,491 trea-
ted with cART. Each patient taking cART had a perso-
nal adherence supporter [28]. In addition, all patients
presenting with tuberculosis were tested for HIV,
enabling thereby early diagnosis and follow-up of HIV/
tuberculosis co-infected patients. After initiation of
cART and clinical stabilization, patients were referred to
a Refilling Centre closer to their living place facilitating
adherence, and returned to the Care and Treatment
Centre only on a three-monthly basis.
Outcome measures and cART
In the survival analysis, we included all HIV-infected
patients who died from all causes within the first year
after starting cART. We also considered all patients
lost to follow-up as failures, since a meta-analysis of
Brinkhof et al. [29] showed that in rural sub-Saharan
African cohorts up to 20 to 69% of patients lost to fol-
low-up that could be retraced had died.
All patients were treated according to NACP guidelines
[30] which are based on the 2002 WHO recommendations
and the 2007 revision of the WHO guidelines [31]. Indivi-
duals were eligible for cART if they: (a) had a WHO stage
4 disease, (b) had proven tuberculosis and a CD4 cell
count between 200 and 350 cells/μl, (c) had a CD4 cell
count below <200 cells/μl or (d) were pregnant irrespec-
tive of CD4 cell count. In addition, every patient with a
WHO stage 3 and more or a CD4 cell count <200 cells/μl
received prophylaxis with co-trimoxazole 400/80 mg/day.
Patients were followed up every month until resolu-
tion of clinical symptoms of an AIDS defining illness
and to the point of achieving two consecutively increas-
ing CD4 cell counts under cART. Thereafter, appoint-
ments were scheduled on a three-monthly basis. At each
visit, signs of tuberculosis were actively investigated.
Laboratory controls included a blood cell count and
chemistry two weeks after initiation of cART and a CD4
cell count after 3 months and every 6 months thereafter.
Measurement of HIV-RNA was not available for the
present study. cART switches due to toxicity or other
reasons were performed in line with the NACP [30].
The same applied for treatment failures defined as a
new or recurrent WHO stage 4 condition, decrease of
CD4 cell count to pre-therapy baseline (or below), a
50% fall from the on-treatment peak value or persistent
CD4 levels below 100 cells/μl.
Adherence support
Each patient receiving cART designated a personal
adherence supporter - mostly a family member or any
other trustworthy person living in the vicinity of the
patient. The supporters received counseling about cART
and side effects, provided assistance in taking cART
throughout the study period and accompanied the
patient at cART initiation and from then on request at
follow-up visit.
Patients with cART who missed visits were contacted
or traced by home based care volunteers where possible.
Data collection and definitions
Data was collected prospectively using standardized
record forms completed at each follow-up visit including
information on the clinical course, occurrence of tuber-
culosis, WHO stage, adherence, laboratory results and
treatment history. Data was entered into the NACP and
the Kilombero and Ulanga Antiretroviral Cohort (KIU-
LARCO) databases. Quality control was performed by
double data entering and cross-checking procedures.
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definition according to WHO guidelines [32]. Tubercu-
losis was diagnosed and treated following WHO guide-
lines within the framework of the National Tuberculosis
and Leprosy Control Programme [33].
cART defined as a combination of at least 3 antiretro-
viral drugs was prescribed following the recommenda-
tions of the NACP [30]. The first-line regime consisted
of a fixed dose combination of nevirapine 200 mg plus
lamivudine 150 mg and stavudine 30 mg (individuals
> 60 kg 40 mg till end of December 2006) twice daily.
Similar immunological and virological outcomes were
found between the two-stavudine doses in patients
weighing more than 60 kg in an African operational
cohort at 6 months [34]. Alternatives were 1 tablet of
nevirapine 200 mg plus a fixed dose combination of
lamivudine 150 mg and zidovudine 250 mg twice daily,
or 1 tablet of efavirenz 600 mg once daily either with
lamivudine 150 mg plus zidovudine 250 mg as a fixed
dose combination or lamivudine 150 mg plus stavudine
30 mg (individuals > 60 kg 40 mg till end of December
2006) twice daily. The second-line treatment was a fixed
dose combination of 2 pills of lopinavir/ritonavir 200/
50 mg plus 1 tablet of abacavir 300 mg twice daily plus
4 tablets of didanosine 100 mg once daily. Treatment
modification was defined as any change of one or more
cART components excluding dosage adjustments. The
main reason for treatment modification was classified as
failure (clinical, immunological), toxicity (nausea/vomit-
ing, rash, peripheral neuropathy, hepatitis, anemia, CNS
adverse events), interactions (start of TB treatment) or
others. Anemia was defined as haemoglobin < 12 g/dl
and was seen as a contraindication for prescribing zido-
vudine. Hepatitis was diagnosed if transaminases
increased > 5 times the upper norm.
Loss to follow-up was defined as not showing up on
two consecutive visits, i.e. for a period of 6 months.
Statistical analysis
Basic socio-demographic characteristics, co-infection
with tuberculosis, HIV clinical stage, CD4 cell count, and
antiretroviral treatment were compared using the Chi-
square test or Fisher’s exact test for categorical variables,
and the Mann-Whitney test for continuous variables.
Cox proportional hazard models were used to investigate
factors associated with survival and loss to follow-up
after starting cART. All patients were censored at
12 months after starting cART if no death or loss to fol-
low-up had occurred. Patients who were lost to follow-up
were considered as failures and censored at the last visit
date. The proportional hazards assumption was checked
using the Schoenfeld test. Logistic regression was used to
explore risk factors of being lost to follow-up during the
first year of cART and as well as predictors of treatment
modification. Multivariate models were built using a for-
ward stepwise approach, adding each factor significant at
the level of 0.1 and other factors defined in the literature
as prognostic in the model one by one. The final model
was examined for interaction using the likelihood ratio
test.
All analyses were performed using STATA™ software
version 9.2 for Windows (StataCorp, College Station,
Texas).
Ethical approval
The research and ethical clearance was obtained from
the Medical Research Coordination Board of the
National Institute for Medical Research, Tanzania,
through the Tanzania Commission for Science & Tech-
nology and from the Ethical Review Board of the Can-
tons Baselstadt and Baselland, Switzerland. Written
informed consent was obtained from all participants
enrolled in the Kilombero and Ulanga Antiretroviral
Cohort (KIULARCO).
Results
Overall, 1,463 treatment-naïve, HIV-infected adults
initiated cART between 1
st January 2005 and 20
th
December 2008. The median age was 40 years (inter-
quartile range [IQR] 34-47), 35.4% were males, and 7.6%
had confirmed tuberculosis. 2.6% of the female indivi-
duals were pregnant. The median CD4 cell count was
131 cells/μl (IQR 54-234) and 24.3% had a WHO clini-
cal stage 4. Patients co-infected with tuberculosis tended
to start cART at higher CD4 cell counts than patients
without tuberculosis (142 versus 117 cells/μl, p = 0.060).
Antiretroviral therapy consisted of a nevirapine-based
regimen in 83.1% of individuals. 75% of all patients were
started on nevirapine/lamivudine/stavudine, 8.1% on
nevirapine/lamivudine/zidovudine, 13.3% on efavirenz/
lamivudine/zidovudine, 1.8% on efavirenz/lamivudine/
stavudine, and 1.8% on other drug combinations.
General characteristics of the study population accord-
ing to the outcome at 12 months are listed in Table 1.
Response to cART
The median CD4 cell count increase was 61 cells/μl
(IQR 10-167) and 130 cells/μl (IQR 43-222) after 6 and
12 months, respectively. In particular, at 6 months and
12 months 49.9% and 70.1% of patients with available
data had CD4 cell counts > 200 cells/μl, respectively,
compared with only 23.6% at starting cART. During the
follow-up, the median increase in body weight was 3 kg
(IQR 0-8), and 115 out of 181 patients (63.5%) with
available data experienced a change of activity from
either bedridden or ambulant to working. Overall, 129
patients (8.8%) died and 189 (12.9%) were lost to follow-
up during the first year of cART.
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cART
In a multivariate model adjusted for age, gender, body
weight, CD4 cell count, the presence of tuberculosis and
antiretroviral regimen, risk factors for poor survival were
lower CD4 cell counts at starting cART (HR 1.77, 95% CI
1.157-2.72, p = 0.009 for CD4 cell count <50 compared
with >100 cells/μl) (Table 2 and Figure 1). In contrast,
higher body weight was strongly associated with better
survival (HR 0.63, 95% CI 0.51-0.76, p < 0.001 per 10 kg
increase) (Table 2). Risk factors for poor survival and loss
to follow-up during the first year of cART are listed in
Table 2.
Treatment modification
During the follow-up, 215 individuals (14.7%) changed their
antiretroviral treatment after a median time of 133 days
(IQR 58-371). The most frequent reason for modifying
cART was toxicity to cART (56.2%), i.e. peripheral poly-
neuropathy in 26.8%, concern of potential drug-drug inter-
actions related to antituberculous therapy in 23.2%, anemia
in 13.9% of patients, and treatment failure in 6.7%. Among
patients with treatment change due to toxicity, the use of
stavudine was clearly associated with an increased risk of
polyneuropathy (OR 28.7, 95% CI 3.85-214.34, p = 0.001),
whereas all 26 patients who changed their treatment due to
anemia were initiated on a zidovudine-containing regimen.
Only one woman modified her initial, efavirenz-containing
antiretroviral therapy due to pregnancy.
The immunological recovery at 12 months did not dif-
fer between patients who changed their treatment and
those who did not (144 cells/μl [IQR 62-230] versus
122 cells/μl ([IQR 33-222], p = 0.289). However, patients
who changed cART showed a higher median increase in
body weight than those who remained on their first
regimen (5 kg [IQR 0.2-10] versus 3 kg [IQR 0-7], p =
0.003). No difference in the mortality rate was noted
according to whether patients had changed their treat-
ment (7.9% versus 9.8%, p = 0.388).
In a multivariate model adjusted for age, sex, CD4 cell
count, body weight, presence of tuberculosis, and cART,
an antiretroviral regimen containing efavirenz and zido-
vudine combined with lamivudine (odds ratio (OR) 1.80,
95% CI 1.11-2.90, p = 0.016, compared to a nevirapine
based regimen) was the only risk factor of treatment
modification within the first year of cART.
Table 1 General characteristics of the adult study population (n = 1463) according to the outcome at 12 months after
starting combination antiretroviral therapy
Characteristics at 12 months All patients
N = 1463
Death or lost to follow-up
N = 318
Alive and on cART
N = 1145
p-value dead vs. alive
n% n % n %
Median age, IQR 40 34-47 40 33-48 40 34-47 0.913
Males 518 35.4 130 40.9 388 33.9 0.021
Marital status Single 213 14.6 24 7.6 189 16.5 <0.001
Married 390 26.7 48 15.1 342 29.9
Divorced or Widowed 277 18.9 37 11.6 240 21.0
No information 583 39.8 209 65.7 374 32.7
Median weight, IQR 50 43-56 45 39-52 51 44-57 <0.001
Median hemoglobin, IQR 9.5 8-11 8.8 7.4-10.7 9.8 8.2-11.1 <0.001
WHO stage I 162 11.1 11 3.5 151 13.2 <0.001
II 155 10.6 7 2.2 148 12.9
III 279 19.0 31 9.8 248 21.7
IV 197 13.5 40 12.6 157 13.7
No information 670 45.8 229 72.0 441 38.5
Median CD4 cell count, IQR 131 54-234 80 27-156 130 60-205 <0.001
Tuberculosis Proven 111 7.6 19 6.0 92 8.0 <0.001
Suspected 538 36.8 62 19.5 476 41.6
cART Nevirapine-based 890 60.8 130 40.9 760 66.4 <0.001
Efavirenz-based 162 11.1 23 7.2 139 12.1
No information 411 28.1 165 51.9 246 21.5
Distance to clinic <10 km 710 48.5 143 45.0 567 49.5 0.561
10-50 km 271 18.5 66 20.7 205 17.9
50-100 km 276 18.9 59 18.5 217 19.0
>100 km 134 9.2 33 10.4 101 8.8
No information 72 4.9 17 5.4 55 4.8
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During the study period, 189 (12.9%) patients were lost
to follow-up. In a multivariate model adjusted for age,
sex, marital status, distance between living place and
the clinic, confirmed tuberculosis and CD4 cell count,
independent risk factors of loss to follow-up were a
CD4 cell count below 100 cells/μl at starting cART (OR
2.55, 95% CI 1.45-4.50, p = 0.001) and living more than
100 km away from the clinic (OR 3.02, 95% CI 1.40-
6.56, p = 0.005).
Death
Overall, 129 patients (8.8%) died during the first year of
antiretroviral therapy. 56 (75.7%) of all patients with a
known cause of death died of an AIDS-defining event
(tuberculosis in 30.4%, bacterial pneumonia in 19.6%,
pneumocystis jirovecii pneumonia in 14.3%, waisting syn-
drome in 10.7%, Kaposi sarcoma in 10.7%, cerebral tox-
oplasmosis in 7.1%, cervical/anal cancer in 3.6% and
candida osophagitis in 3.6%). 18 individuals died of
other causes (gastroenteritis in 5, cardiovascular disease
in 4, severe anemia in 3, malaria in 2, peritonitis in 2,
rectum carcinoma in 1 and road accident in 1 patient).
The cause of death remained unknown in 55 patients.
Time to death or loss to follow-up during the first
year after starting cART according to the baseline CD4
cell count cells/μl is shown in Figure 1.
Discussion
In this prospective cohort study including 1,463 HIV-
infected treatment-naïve adults who started cART
between 2005 and 2008 assisted by a personal adherence
supporter, improved survival was associated with higher
initial CD4 cell counts and better general health condi-
tion. One out of 7 individuals changed their cART,
mostly due to adverse side effects such as peripheral
polyneuropathy and anemia. The immunological recov-
ery was comparable to other studies, although impor-
tantly a considerable number of HIV-infected patients
died or were lost to follow-up during the first year of
Table 2 Risk factors for poor survival and loss to follow-up during the first year of cART, hazard ratios (HR), univariate
and multivariate analysis
Characteristics Univariate analysis Multivariate analysis
§
HR 95% CI p-value HR# 95% CI p-value
Age, per 10 years older 0.98 0.87-1.09 0.669 0.97 0.80-1.17 0.760
Female 0.77 0.62-0.97 0.025 0.77 0.52-1.15 0.201
Weight, per 10 kg increase 0.61 0.54-0.69 <0.001 0.63 0.51-0.76 <0.001
Tuberculosis Absent 1* - - 1* - -
Suspected 0.49 0.37-0.68 <0.001 0.63 0.44-1.10 0.082
Confirmed 0.73 0.45-1.16 0.180 1.28 0.70-2.33 0.421
CD4 cell count >100 1* - - 1* - -
50-100 1.50 1.07-2.11 0.018 1.37 0.82-2.29 0.230
<50 2.31 1.77-3.04 <0.001 1.77 1.15-2.72 0.009
cART Nevirapine-based 1* - - 1* - -
Efavirenz-based 1.13 0.71-1.79 0.607 0.91 0.54-1.52 0.712
# adjusted for all variables listed in the table.
* reference category.
§ Global test of proportional hazards assumption (Schoenfeld): p = 0.248.
 
p<0.001
Figure 1 Time to death or loss to follow-up during the first
year after starting cART according to the baseline CD4 cell
count cells/μl.
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tion bias.
Study population and treatment response
The age-sex distribution of this cohort was comparable
to most studies from sub-Saharan Africa with about one
third being male [12,14,23,35-39]. The median CD4 cell
count at cART initiation, i.e. 131 cells/μl, was slightly
higher than in some settings [8,14,23,35-38]. Two cohorts
[12,40] from Zambia and Rwanda and a recent systematic
review in sub-Saharan Africa [41] showed a high varia-
tion of CD4 cell counts at baseline with mostly compar-
able CD4 cell counts at baseline. Patients co-infected
with tuberculosis tended to start cART at higher CD4
cell counts, possibly reflecting earlier diagnosis of HIV in
symptomatic patients. The median CD4 cell increase of
130 cells/μl after 12 months of cART was comparable to
the immunological recovery reported in the large cART-
LINC Collaboration multinational analysis and the Rwan-
dan National Programme [36,37,40], but was lower than
in smaller cohorts [12,14,38,39,42-44]. Importantly, CD4
cells surpassed the 200 CD4 cell level in most individuals
in our cohort.
Treatment change and toxicity
Due to differences in study modeling, in the observation
period and in assessing the reason for switching, com-
parison of the rate of treatment change was prone to
misinterpretation in the different studies evaluated
[8,14,35,43,45,46]. This was additionally enhanced by the
fact that toxicity due to stavudine accumulated over
time whereas toxicity to nevirapine, efavirenz, lamivu-
dine and zidovudine occurred earlier in the course of
cART. The range of cART switches lay between 8%-
21.9% in sub-Saharan Africa [8,14,35,43,45,46]. However,
we found a higher rate of polyneuropathy despite a
similar use of stavudine. Possibly, the high consumption
of cassava in the catchment area of our clinic known to
induce endemic polyneuropathy may have increased this
toxicity [47-50]. A regimen containing efavirenz and
zidovudine combined with lamivudine was associated
with a 2-fold higher risk of treatment modification
within the first year of cART, possibly due to an
enhanced effect of zidovudine on a pre-existing anemia
in a hyperendemic area of malaria.
Risk factors for poor survival
CD4 cells of less than 50 cells/μl and low body weight at
starting cART reflecting late presentation were indepen-
dent risk factors for poor survival in our cohort, findings
shared with other cohorts [8,12,14,23,38,42,43,46,51-54].
Additionally, May et al. [55] found male sex, age > 40
years and severe anemia to be prognostic. Interestingly,
active tuberculosis was not a risk factor for poor survival
in our cohort, although tuberculosis has been estimated
to cause about one third of all deaths of HIV-infected
individuals in sub-Saharan Africa [4,43,52]. However,
our study may be underpowered to detect differences in
survival as only few patients had tuberculosis. Note-
worthy, patients with tuberculosis were enrolled for
treatment at higher CD4 cell counts. All patients had a
mandatory adherence supporter, but data collection on
adherence itself was inconsistent. Hence, we could not
analyze adherence in this setting as in comparable Afri-
can settings [14,24,25,46], where good adherence was
shown to be associated with improved outcome under
cART.
In our study, a considerable proportion of patients
died or was lost to follow-up adding up to 21.7% during
the first year of cART. Three comprehensive reviews
[ 5 6 - 5 8 ]s h o w e dt h a ta t t r i t i o nw a sh i g h e s td u r i n gt h e
first year on cART and 12-months’ retention rate ranged
between 55%-93% [56-58] with an average rate of 75.2%-
77.5% [57,58], which was comparable to our evaluation.
Loss to follow-up was found to be more likely in indivi-
duals with WHO stage 4, CD4 cell count less than
50 cells/μl [42,43,51] and within the first 3 months of
starting cART [47,51]. We assume that a significant part
o ft h e s ep a t i e n t sh a v ed i e da sa ne v a l u a t i o nb yB r i n k h o f
showed [29]. The remote rural setting with distances up
to 150 kilometers from the treatment centre may have
contributed to this result [23,59]. Nevertheless, the
1-year survival on cART was comparable with other stu-
dies including urban settings [8,35,42,47,51-58].
Limitations and strengths
We acknowledge some limitations of our study. First,
data on follow-up was not complete for all patients, pos-
sibly leading to an overestimation of cART effectiveness
in this setting. Secondly, a significant proportion of
patients were lost to follow-up (14.8%). However, as we
considered that these latter patients experienced treat-
ment failure this may have accounted for an underesti-
mation of cART effectiveness. Thirdly, viral load could
not be measured which has important implications for
the definition of treatment failure. Moreover, the exact
cause of death was not known in 43% of all patients.
This may have lead to a survival bias as tuberculosis
m a yh a v ea c c o u n t e df o ras u b s t a n t i a lp r o p o r t i o no f
deaths. Adherence could not be included in our analysis
due to inconsistency of data. Due to the large propor-
tion of missing data for certain variables, we could not
include all investigated factors in the multivariate analy-
sis. WHO’s 2010 guidelines [60] promote tenovofir as
one of the first line compounds of cART, which limits
the relevance of our data to a certain extent. Neverthe-
less, stavudine will probably remain for a while due to
its low costs, wide availability and being an alternative
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HIV associated nephropathy [61-63] and increasing pre-
valence of arterial hypertension and diabetes mellitus
contributing to impaired renal function. This may espe-
cially be relevant in settingsw i t hh i g hp r e v a l e n c eo f
anemia due to malaria and nutritional deficiencies
where zidovudine can’t be readily used.
The strengths of our study are manifold. The care and
treatment facility at St. Francis Designated District Hos-
pital is among the largest centres offering cART in a
remote rural setting of Eastern Africa. Data was collected
prospectively allowing more precise assessment of treat-
ment efficacy. Data was derived from one centre there-
fore avoiding any leveling effects and high heterogeneity.
Also, our site strictly follows the Tanzanian guidelines of
the NACP and was uniquely supplied by the NACP
which directly reflects a reach-out antiretroviral treat-
ment programme with a public health approach. All indi-
viduals in this study were treatment-naïve at the start of
cART. Therefore, results are not affected by previous
exposure to antiretrovirals. Finally, our cohort is one of
the largest rural HIV-cohorts in sub-Saharan Africa
[13,23-27] showing a 1-year survival on cART similar to
studies performed in urban settings [8,35,42,46,51,52],
where education is higher, infrastructures, skilled human
resources, patient support and referral systems are better
than in a rural setting. Starting cART with the support of
a treatment assistant may have helped to overcome many
of the above mentioned constraints of a rural setting
[64,65]. These findings strongly support the feasibility of
WHO’sp o l i c yo f“rolling and reaching out” [5] to rural
sites in sub-Saharan Africa.
Conclusions
In conclusion, cART initiation at higher CD4 cell counts
and better general health condition can reduce HIV
related mortality in a rural African setting. The principle
of starting cART only with a treatment assistant may
help to overcome the constraints of a rural setting and
allows comparable treatment outcomes as in urban
cohorts. Efforts must be made to promote earlier HIV
diagnosis in order to start cART timely and improve
survival in rural African regions with moderate to high
HIV prevalence. This necessitates wider voluntary HIV
testing and counselling.
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